There is no cure for multiple sclerosis (MS), but the outlook for people living with the disease has changed dramatically over the past two decades. Modern treatments can significantly reduce relapses, slow disability progression, and in some cases halt visible disease activity for years. People diagnosed today are more likely to live to age 80 than those diagnosed a generation ago, and several promising research directions could reshape treatment even further.
What Current Treatments Can Do
While no therapy eliminates MS entirely, disease-modifying therapies (DMTs) are the cornerstone of managing relapsing forms of the disease. More than 20 DMTs are now available, and they work by calming the immune system’s attack on the protective coating around nerves. In clinical comparisons, these medications reduced annual relapse rates by 18% to 71% compared to placebo, depending on the specific drug and its potency. Higher-efficacy options, particularly infusion therapies, tend to deliver the strongest results.
Starting treatment early matters. Neurologists increasingly push for aggressive therapy soon after diagnosis because nerve damage from MS accumulates over time and is largely irreversible once it occurs. The goal is to reach a state called “no evidence of disease activity,” meaning no relapses, no new brain lesions on MRI, and no worsening disability. For many people on high-efficacy therapy, this is achievable for extended stretches, sometimes years at a time. That’s not a cure, but it can look and feel like one in daily life.
These treatments come at a steep cost. In the United States, the average list price for oral MS medications reached roughly $104,000 per year by 2021, while infusion-based therapies averaged around $92,000 annually. Net prices after manufacturer discounts are lower but still substantial, ranging from about $67,000 to $96,000 depending on the drug.
Stem Cell Transplants: The Closest Thing to a Reset
Autologous hematopoietic stem cell transplantation (HSCT) is the most aggressive treatment currently available for MS. It essentially reboots the immune system: your own stem cells are collected, chemotherapy wipes out the existing immune system, and the stem cells are reinfused to rebuild it from scratch. The idea is that the new immune system will no longer attack the brain and spinal cord.
Long-term data published in the journal Neurology show meaningful results. Among people with relapsing-remitting MS, about 62% had no evidence of disease activity five years after transplant, and roughly 40% maintained that status at ten years. With the most intensive treatment protocol, those numbers climbed to 68% and 55%, respectively. Even people with progressive MS saw benefit: about 51% achieved no evidence of disease activity at five years.
HSCT is not without serious risks. The chemotherapy phase carries dangers including infection and organ damage, and the procedure requires weeks of hospitalization and months of recovery. It is generally reserved for people with highly active relapsing MS who have not responded well to conventional therapies. It also works best when started earlier in the disease course, before significant irreversible damage has accumulated. For the right candidate, though, it can produce years of stability without ongoing medication.
Why Progressive MS Is Harder to Treat
Most MS treatments target the inflammatory attacks that drive the relapsing-remitting form of the disease. But many people eventually transition to a progressive phase where disability worsens gradually, driven less by dramatic immune flare-ups and more by a slow, smoldering process of nerve damage inside the brain and spinal cord. Only a handful of approved therapies have shown any benefit in progressive MS, and their effects are modest.
A new class of drugs called BTK inhibitors is generating significant interest precisely because they can cross into the brain and potentially quiet this smoldering inflammation directly. Four BTK inhibitors are in advanced clinical testing. Two of them have trials specifically targeting primary progressive MS and non-relapsing secondary progressive MS, which are the hardest forms of the disease to treat. In lab models, one of these drugs significantly reduced disease severity when given early and showed a smaller but measurable benefit even when started after symptoms appeared. Phase 3 trial results in humans will clarify whether this translates into real-world benefit.
Repairing Damaged Nerves
Stopping new damage is only half the equation. The other half, and the one that would bring treatment closer to a true cure, is repairing the myelin sheath that MS destroys. Myelin is the insulating layer around nerve fibers that allows electrical signals to travel quickly. When it’s stripped away, signals slow down or fail entirely, producing the numbness, weakness, vision problems, and cognitive difficulties associated with MS.
The brain naturally contains cells that can produce new myelin, but in MS these repair cells often stall before finishing the job. Researchers are now testing drugs designed to nudge these cells into action. One candidate, PIPE-307, is in a phase 2 trial involving 168 people with relapsing-remitting MS. It works by blocking a specific receptor on immature myelin-producing cells, which appears to help them mature and begin laying down new insulation. The trial is measuring whether the drug improves low-contrast vision, a sensitive indicator of nerve fiber health. If remyelination therapies prove successful, they could potentially restore lost function rather than simply preventing further decline.
Could MS Be Prevented Entirely?
One of the most striking findings in MS research is the connection to the Epstein-Barr virus (EBV), the common virus that causes mononucleosis. Epidemiological evidence now strongly suggests that EBV infection is a necessary step in the development of MS. People who have never been infected with EBV are essentially protected from getting the disease. The exact mechanism linking the virus to MS remains unknown, but late, symptomatic EBV infection (mono) is a more significant risk factor than catching the virus early in childhood without symptoms.
This has sparked efforts to develop an EBV vaccine, not as a treatment for existing MS, but as a way to prevent new cases from developing in the first place. Researchers have argued that preventing mono at a population level through vaccination is more feasible than trying to identify and protect only high-risk individuals, such as family members of people already diagnosed. A successful EBV vaccine would represent a fundamentally different kind of breakthrough: not a cure, but something potentially more powerful in the long run.
Better Monitoring Is Changing Outcomes
Alongside new treatments, the ability to track MS activity is becoming more precise. A blood test measuring neurofilament light chain (NfL) can detect nerve damage in near real-time. When nerve fibers are injured, they release this protein into the bloodstream, where levels remain elevated for about three months after damage occurs. Rising NfL levels can signal disease activity even when a person feels fine and before new lesions show up on MRI.
This blood test allows doctors to assess whether a treatment is working, predict relapse risk, and catch subclinical disease activity that would otherwise go unnoticed. Expert recommendations suggest checking NfL levels every three to six months after a relapse, after an MRI shows new activity, or when evaluating how well a new therapy is performing. The practical impact is that treatment adjustments can happen sooner, reducing the accumulation of hidden damage that drives long-term disability.
Diagnosis itself has also become faster. The 2024 revisions to the McDonald diagnostic criteria now recognize the optic nerve as a fifth anatomical location that can help confirm MS, and newer MRI markers and spinal fluid tests can provide supporting evidence in ambiguous cases. The revised criteria also offer guidance for diagnosing MS in older adults and in people whose earliest signs don’t involve a clear clinical attack. Earlier diagnosis means earlier treatment, which means less irreversible damage.
Living Longer With MS
The cumulative effect of better drugs, earlier diagnosis, and more precise monitoring is showing up in survival data. A 2026 study from University College London found that people diagnosed with MS in more recent years are significantly more likely to reach age 80 and have lower annual mortality rates than those diagnosed in earlier decades. A life expectancy gap between people with MS and the general population still exists, but it is narrowing. The combination of high-efficacy treatments started early, regular monitoring with tools like NfL blood tests, and the prospect of future therapies that repair nerve damage or prevent the disease altogether paints a more hopeful picture than at any previous point in MS research.